References in periodicals archive ?
Results of multivessel percutaneous transluminal coronary angioplasty in persons aged 65 years and older.
This report analyzes the worldwide markets for Percutaneous Transluminal Coronary Angioplasty (PTCA) Products in US$ Million by the following product types:
Bioabsorbable stents, Percutaneous Transluminal Coronary Angioplasty (PTCA) coronary Drug Eluting Balloons (DEB) and Intravascular Ultrasound Systems (IVUS) are expected to drive the growth of the market through better efficacy and safety profiles, reduced procedure time and reduced procedure cost.
The AngioSculpt[R] Percutaneous Transluminal Coronary Angioplasty (PTCA) Scoring Balloon Catheter received FDA Pre-market Application (PMA) Approval for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
Keywords: Interventional cardiology, cardiology devices, vascular, drug-eluting stents, bare-metal stents, percutaneous transluminal coronary angioplasty (PTCA) and cutting balloons catheters, balloon-inflation devices, angioplasty accessory kits, interventional catheters and guidewires, diagnostic catheters and guidewires, coronary introducer sheaths, embolic protection devices, atherectomy devices, thrombectomy devices, chronic total occlusion (CTO) devices, vascular closure devices (VCDs) and intravascular ultrasound (IVUS) catheters
In January 2007, AngioScore's companion product, the AngioSculpt[R] Percutaneous Transluminal Coronary Angioplasty (PTCA) Scoring Balloon Catheter, received FDA Pre-market Application (PMA) Approval for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
Aggrastat[R] is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous transluminal coronary angioplasty (PTCA).
The European percutaneous transluminal coronary angioplasty (PTCA) balloon market, comprising both normal and cutting balloons, was valued in excess of $180 million.
Angiomax is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA) and with provisional GP IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention (PCI).
In June, the label was expanded to include PCI in addition to patients undergoing percutaneous transluminal coronary angioplasty (PTCA).